If successfully developed, this oral formulation may support the evaluation of Telintra in additional hematologic disorders characterized by low levels of one or more of the three blood cell lineages.
Myelodysplastic syndrome (MDS), the most common hematologic malignancy in the elderly, causes ineffective formation of blood elements manifested by anemia, neutropenia and thrombocytopenia.
The disease may be chronic, characterized by frequent transfusions and iron overload, infections and bleeding, or it may be aggressive with expected survival less than one year. The disease may also progress to acute leukemia.
There are an estimated 10,000 to 15,000 new cases of MDS diagnosed annually in the US, according to the American Cancer Society.